Altay Therapeutics is unlocking the therapeutic potential of transcription factor inhibition to address serious, underserved diseases. The company's pipeline includes the first oral small molecule inhibitor of DUX4 for facioscapulohumeral muscular dystrophy (FSHD) and a potential best-in-class STAT3 inhibitor with broad potential in cancer and chronic inflammatory diseases.